Detailed Instructions: Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
See one example below:
Problem: "Although the story didn't cite the cost of appendectomy emergency or urgent surgery and we wish it had, we nonetheless will give it a satisfactory score because it at least cited what the editorial writer wrote, ""A secondary benefit is the savings to the hospital generated by minimizing staff and anesthesiologist presence late in the evening and during the wee hours of the morning."" As with our harms score above, although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Despite running less than 300 words, this story did an adequate job in explaining the quality of the evidence, including pointing out limitations. No disease-mongering here. The story meets the bare minimum requirement for this criterion in that it at least cited what an editorial stated. The focus of the story was on a study comparing emergency appendectomy with surgery done up to 12 hours later or beyond. This is the whole focus of the story and one we applaud when it begins: ""Appendectomy is the most common emergency surgery in the world, but it doesn't have to be."" There were no claims made about the novelty of this research, and we may have wished for a bit more context on this. Nonetheless, the potential for guiding future care decisions was made clear. Not applicable. Given that the story only pulled excerpts from the journal article and the accompanying editorial, and didn't include any fresh quotes from interviews, we can't be sure of the extent to which it may have been influenced by a news release."
Solution: Some appendicitis cases may not require 'emergency' surgery
Explanation: The paragraph mentions that "Appendectomy is the most common emergency surgery in the world, but it doesn't have to be." which is considered evidence for the output. Thus, the output is a valid claim.

Problem: UCB shares dropped as much as 18.4 percent to 21.60 euros, their lowest level since August 2003, as investors took a dim view of the latest in a series of setbacks to hit the group. This month, U.S. health officials warned its prescription cough medicine Tussionex could be fatal for young children if taken frequently, though it is not approved for those aged under six. UCB has also yet to convince regulators its would-be blockbuster Cimzia should be cleared for treating the bowel disorder Crohn's disease. The European Medicines Agency on Thursday reaffirmed its view that Cimzia should not be approved. Last year, UCB achieved net sales of 52 million euros ($81.7 million) from Neupro, a relatively new product. "Depending on the resolution timeline of this issue, the full effect on UCB's business is not yet known. Therefore, UCB's 2008 financial outlook is under review and will be updated as soon as possible," the company said in a statement. UCB said the recall decision was not the result of contamination or toxicity but that the clinical performance of some samples on the market was not as required. "As a result, there will be an out-of-stock situation with Neupro in the United States in late April 2008. In the European Union and most other regions, Neupro supply is sufficient," it continued. A spokeswoman said it was not clear how long UCB would be out of stock in the U.S. and likewise when it would be able to give a new 2008 outlook. KBC Securities said in a research note it had reduced its forecast for Neupro sales this year to 88 million euros from 110 million, as well as its peak annual sales estimates and cut its target price to 33.50 euros from 35.00 euros. "This disruption comes at a crucial time in the launch phase of this important franchise," Deutsche Bank wrote, adding Neupro's launch for restless legs could be significantly delayed by regulators' insistence that quality problems be resolved. Neupro, delivered to patients in the form of patches stuck on the skin, is approved to treat early-stage Parkinson's in the U.S. and early and late stages of the disease in Europe. The patches were launched in Europe in 2006 and in the U.S. in July 2007. It filed for approval to treat restless legs syndrome in the United States and Europe in December. UCB last month forecast revenue would decrease to about 3.4 billion euros in 2008 from 3.6 billion last year. Recurring core profit (EBITDA) would be about 650 million euros and net profit was expected to exceed 100 million.
Solution:
UCB recalls Parkinson's patch, reviews 2008 outlook.